Papalocal
Loading…
News
← All news
Health

One CRISPR injection cut bad cholesterol by 52% — and the effect held for a full year

A first-in-human trial of gene-editing therapy CTX310 showed durable lipid reductions at 12 months with no serious treatment-related side effects, clearing the way for larger trials.

How does this story make you feel?

A single infusion of an experimental gene-editing therapy has kept 'bad' LDL cholesterol roughly half as low as it was before treatment — and the effect is still holding a full year later, with no serious side effects linked to the drug. The results, published in the New England Journal of Medicine and presented at the European Society of Cardiology Congress 2026, mark the longest follow-up yet for a CRISPR-based approach to treating lipid disorders.

The therapy, called CTX310 and developed by CRISPR Therapeutics AG in Switzerland, was tested in 15 adults at the Cleveland Clinic whose cholesterol or triglyceride disorders had already failed to respond to conventional medications. Participants received a one-time intravenous infusion — pre-treated with corticosteroids and antihistamines to prevent immune reactions — at doses ranging from 0.1 to 0.8 mg/kg based on estimated lean body weight.

Among the four patients who received the highest dose of 0.8 mg/kg, LDL cholesterol fell by an average of 52.5% from baseline at 12 months, triglycerides dropped 47.8%, and levels of ANGPTL3 — the liver protein the therapy targets — fell by 78.6%. No dose-limiting toxicities or new serious adverse events related to CTX310 were reported during the full year of follow-up.

The durability of the lipid-lowering effect was impressive. It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment. We look forward to continuing to investigate this therapy in a larger number of patients.— Dr. Luke Laffin, cardiologist and co-first author, Cleveland Clinic

CTX310 works by delivering CRISPR-Cas9 gene-editing components — packaged inside lipid nanoparticles — into liver cells called hepatocytes. Once inside, the therapy permanently switches off the ANGPTL3 gene. The protein produced by that gene normally inhibits enzymes that clear fats from the blood; turning it off allows the body to process LDL cholesterol and triglycerides more efficiently. Crucially, some people are born with natural loss-of-function variants in the same gene and experience lifelong reductions in LDL cholesterol and cardiovascular risk without apparent ill effects — a biological precedent that motivated the therapy's design.

The durability finding addresses a fundamental question about gene editing in the liver. Hepatocytes divide and replace themselves — Cleveland Clinic's Dr. Steven Nissen, Chief Academic Officer of the Heart, Vascular & Thoracic Institute, notes that liver cells turn over at nearly 20% per year, meaning the average adult liver cell is less than three years old regardless of a person's age. If edited cells are simply replaced by unedited ones over time, the therapeutic effect would fade.

The levels of ANGPTL3 and lipids remained low and flat through the full year, which suggests we're editing the genes so efficiently that when the hepatocytes replicate, the genetic change we've induced is replicated along with them.— Dr. Steven Nissen, Chief Academic Officer, Cleveland Clinic Heart, Vascular & Thoracic Institute
The most compelling feature of gene-editing approaches for treating disease is that they represent the potential for a cure rather than chronic management with medications.— Dr. Luke Laffin, cardiologist and co-first author, Cleveland Clinic

One participant died 179 days after treatment; the researchers concluded the death was unrelated to CTX310, according to Science Alert. In the remaining 14 participants, reduced cholesterol and triglyceride profiles continued through the follow-up period.

The phase 1a trial is now complete, and a phase 1b trial is underway. That next phase is testing a fixed dose corresponding to the highest dose used in phase 1a — the 0.8 mg/kg level that produced the most significant results — in separate cohorts of patients with specific lipid disorders, according to the researchers' published paper.

Separately, results presented at the American Heart Association's annual meeting in Chicago showed CTX310 reduced triglyceride levels by 63% to 85% in 10 adults with severe hypertriglyceridemia within 30 days of a single injection, according to Good News Network.

Experts not involved in the trial were quick to note both the promise and the practical limits of the approach. The 50% LDL reduction achieved by CTX310 at the highest dose is comparable to what daily statin pills can achieve, according to BBC Science Focus. But statins are inexpensive and widely available — a contrast that shapes how gene-editing therapies are likely to be deployed.

The issue with a statin is you have to take a pill every day of your life. So the big advantage of a one-off treatment is: that's it. You don't have to worry about any of that stuff.— Prof Steve Humphries, cardiovascular genetics expert, University College London
When you have a global population of eight billion people and the number one cause of death is cardiovascular disease, you're trying to find a cost-effective way of reducing that. Given that statins are pretty safe and well-tolerated by the majority, it's going to be statins.— Prof Kosh Ray, cardiologist and public health expert, Imperial College London

Ray points out that delivering CTX310 requires bringing patients in for an infusion of both the drug and additional medications to prevent immune reactions, along with outpatient clinics and trained staff — infrastructure he considers currently unfeasible at population scale, at least in the UK. He estimates that even a one-time gene-editing therapy is 'probably cheaper' than daily statins only when the upfront cost is weighed against lifetime medication, and he doubts that calculation favors gene editing for the general population.

The more likely near-term candidates are patients for whom statins are insufficient. Prof Riyaz Patel, a cardiologist at University College London, points to people who need lifelong lipid-lowering but struggle with daily medication regimens. Ray singles out patients with homozygous familial hypercholesterolaemia — a genetic condition affecting roughly 1 in 300,000 people — whose cholesterol levels are so extreme from childhood that they can die of a heart attack before their teenage years. For such patients, a one-time intervention that permanently alters the underlying biology could be transformative.

For patients who need lifelong lipid-lowering, these 'one-and-done' treatments may offer a future with fewer pills.— Prof Riyaz Patel, cardiologist, University College London

The FDA has requested that all patients in the CTX310 trial be followed for 15 years — an unprecedented duration of required surveillance for a gene-editing therapy. Dr. Nissen explained that the extended monitoring is primarily a safety measure, to detect any downstream consequences of permanently editing a gene, such as malignancy, rather than a concern about whether the cholesterol-lowering effect will persist.

This is encouraging for the entire field of CRISPR, because it suggests that a one-and-done treatment approach really might be possible for many of the gene-editing targets now being looked at.— Dr. Luke Laffin, cardiologist and co-first author, Cleveland Clinic

Why it matters — If confirmed safe over the long term, a single injection that permanently lowers bad cholesterol by half could transform treatment for the millions of patients whose lipid disorders don't respond to daily medication — and raise broader questions about whether gene editing could eventually replace lifelong drug regimens.

⚠ Not yet confirmed

  • The 53% LDL reduction figure cited by BBC Science Focus differs slightly from the 52.5% reported in the NEJM publication and by other outlets

Reported by goodnewsnetwork.org, consultqd.clevelandclinic.org, sciencealert.com, natap.org, sciencefocus.com

Community

Be the first to comment.

Share this story
Text Email